An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring

Assessing the benefit–risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer

(2015) J Péron et al.   BRITISH JOURNAL OF CANCER

Evaluation of multi-outcome longitudinal studies

(2015) Signe M. Jensen et al.   STATISTICS IN MEDICINE

An alternative approach to confidence interval estimation for the win ratio statistic

(2014) Xiaodong Luo et al.   BIOMETRICS

Minimal Clinically Important Difference

(2014) Anna E. McGlothlin et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Use of composite endpoints in clinical trials

(2014) Abdul J. Sankoh et al.   STATISTICS IN MEDICINE

The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities

(2011) S. J. Pocock et al.   EUROPEAN HEART JOURNAL

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial

(2011) Matthew T Seymour et al.   LANCET

Health outcomes in economic evaluation: the QALY and utilities

(2010) S. J. Whitehead et al.   BRITISH MEDICAL BULLETIN

Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field

(2010) Linda Wittkop et al.   Clinical Trials

Generalized pairwise comparisons of prioritized outcomes in the two-sample problem

(2010) Marc Buyse   STATISTICS IN MEDICINE

The Concordance IndexCand the Mann-Whitney Parameter Pr(X>Y) with Randomly Censored Data

(2009) James A. Koziol et al.   BIOMETRICAL JOURNAL

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

QALYs: The Basics

(2009) Milton C. Weinstein et al.   VALUE IN HEALTH

Reformulating the hazard ratio to enhance communication with clinical investigators

(2008) Marc Buyse   Clinical Trials